Quality of life in brain metastases radiation trials: a literature review

J Wong, A Hird, A Kirou-Mauro, J Napolskikh, E Chow, J Wong, A Hird, A Kirou-Mauro, J Napolskikh, E Chow

Abstract

Background: An estimated 20%-40% of cancer patients will develop brain metastases. Whole-brain radiotherapy (WBRT) is the standard treatment for patients with brain metastases. Although WBRT can reduce neurologic symptoms, the median survival following WBRT is between 3 and 6 months. Given this limited survival, it is important to consider quality of life (QOL) when treating patients with brain metastases. However, few studies have focused on QOL and improvement in patient-rated symptoms as primary outcomes.

Objective: For an accurate measurement of the extent to which previous trials have utilized QOL tools to evaluate the efficacy of WBRT for treatment of brain metastases, we undertook a literature review to examine the common endpoints and QOL instruments used.

Methods: We conducted a systematic search using the medline (1950 to December 2007) and Cochrane Central Register of Controlled Trials (4th quarter 2007) databases. Eligible studies investigated WBRT in one of the study arms. The following outcomes were included: median survival, overall survival, neurologic function, 1-year local control, and overall response; use of QOL instruments, performance status scales, and neurologic function assessments; and use of other assessment tools. Patient-rated QOL instruments were defined as those that strove to assess all dimensions of QOL; observer-rated performance instruments such as the Karnofsky performance status (kps) were deemed to be performance scales.

Results: We identified sixty-one trials that included WBRT as a treatment for brain metastases. Of these sixty-one trials, nine evaluated the treatment of a single brain metastasis, and fifty-two evaluated the treatment of multiple brain metastases. Although fifty-five of the trials employed a QOL instrument, few trials focused on QOL as an outcome. We found 23 different instruments used to evaluate QOL. The most commonly employed instrument was the kps (n = 33), followed by various neurologic function classification scales (n = 21). A preponderance of the studies used 1 (n = 26, 43%) or 2 (n = 21, 34%) QOL instruments. A total of fourteen published trials on brain metastases included an evaluation of the study population's QOL. Those trials included three that used the Functional Assessment of Cancer Therapy-General scale and Brain subscale instrument, three that used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (C30) and the Brain Cancer Module 20 instrument, two that used study-designed QOL instruments, one that used the Edmonton Symptom Assessment Scale, two that used the Spitzer Quality of Life index, and three that used the kps to evaluate QOL. Some trials reported deterioration in QOL after WBRT in patients with poorer prognosis; other trials detected an improvement in QOL after WBRT in patients with better prognosis.

Conclusions: To date, fourteen trials in brain metastases that have included an evaluation of the study population's QOL have been published. Although some studies showed that certain parameters of QOL deteriorate after WBRT, other studies showed that QOL in patients with better prognosis is improved after WBRT. Because a standard, validated QOL instrument has not been used for this patient population, a comparison of findings concerning QOL between the studies is difficult. The present review emphasizes the need to include QOL measures in future WBRT clinical trials for brain metastases.

Keywords: Brain metastasis; quality of life; whole-brain radiotherapy.

References

    1. Loeffler JS, Patchell RA, Sawaya R. Treatment of metastatic cancer. In: Devita VT, Hellman S, Rosenburg SA, editors. Cancer: Principles and Practice of Oncology. 5. Philadelphia: Lippincott–Raven Publishers; 1997. pp. 2523–2536.
    1. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol. 1980;7:529–41.
    1. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer. 1997;21:129–83.
    1. Posner JB. Management of central nervous system metastasis. Semin Oncol. 1977;4:81–91.
    1. Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J. Adjuvant treatment of brain metastases. Semin Surg Oncol. 2001;20:50–6.
    1. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase iii study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (rtog) 9104. Int J Radiat Oncol Biol Phys. 1997;39:571–4.
    1. Robinet G, Thomas P, Breton JL, et al. Results of a phase iii study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe francais de pneumo-cancerologie (gfpc) protocol 95-1. Ann Oncol. 2001;12:59–67.
    1. Postmus PE, HaaxmaReiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase iii study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 2000;18:3400–8.
    1. DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol. 1989;7:241–7.
    1. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1–9.
    1. Tsao MN, Lloyd NS, Wong RK, et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2005;31:256–73.
    1. World Health Organization. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference; New York, NY, U.S.A. June 19–22, 1946; Signed on July 22, 1946 (Official Records of the World Health Organization, no. 2, p. 100). Entered into force on April 7, 1948. [Available online at: ; cited September 10, 2008]
    1. Yancik R, Edwards BK, Yates JW. Assessing the quality of life of cancer patients: practical issues in study implementation. J Psychosoc Oncol. 1989;7:59–74.
    1. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–9.
    1. Tannock IF. Treating the patient, not just the cancer. N Engl J Med. 1987;317:1534–5.
    1. Bezjak A, Adam J, Panzarella T, et al. Radiotherapy for brain metastases: defining palliative response. Radiother Oncol. 2001;61:71–6.
    1. Chow E, Davis L, Holden L, Tsao M, Danjoux C. Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage. 2005;30:18–23.
    1. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase iii results of the rtog 9508 randomised trial. Lancet. 2004;363:1665–72.
    1. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–34.
    1. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of rtog trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33:339–48.
    1. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys. 1977;2:1091–4.
    1. Noordijk EM, Vecht CJ, HaaxmaReiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–17.
    1. Eyre HJ, Ohlsen JD, Frank J, et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. J Neurooncol. 1984;2:325–30.
    1. Rhomberg W, Eiter H, Boehler F, Saely C, Strohal R. Combined razoxane and radiotherapy for melanoma brain metastases. A retrospective analysis. J Neurooncol. 2005;74:295–9.
    1. Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer. 1999;7:332–5.
    1. Murray KJ, Scott C, Zachariah B, et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04. Int J Radiat Oncol Biol Phys. 2000;48:59–64.
    1. Haie–Meder C, Pellae–Cosset B, Laplanche A, et al. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol. 1993;26:111–16.
    1. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470–6.
    1. Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the national cancer institute-supported community clinical oncology program. J Clin Oncol. 2005;23:591–8.
    1. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65:1864–6.
    1. Grieco A, Long CJ. Investigation of the Karnofsky performance status as a measure of quality of life. Health Psychol. 1984;3:129–42.
    1. Ochs J, Mulhern R, Kun L. Quality of life assessment in cancer patients. Am J Clin Oncol. 1988;11:415–21.
    1. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.
    1. Epstein BE, Scott CB, Sause WT, et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer. 1993;71:1362–7.
    1. Auchter RM, Lamond JP, Alexander E, et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys. 1996;35:27–35. [See comment]
    1. Jyothirmayi R, Saran FH, Jalali R, et al. Stereotactic radiotherapy for solitary brain metastases. Clin Oncol (R Coll Radiol) 2001;13:228–34.
    1. Li B, Yu J, Suntharalingam M, et al. Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer. 2000;90:37–45.
    1. Roos DE, Wirth A, Burmeister BH, et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized trans-Tasman Radiation Oncology Group trial (trog 98.05) Radiother Oncol. 2006;80:318–22.
    1. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111:334–6.
    1. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol. 1994;17:234–8.
    1. Chang DB, Yang PC, Luh KT, Kuo SH, Hong RL, Lee LN. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest. 1992;101:1293–7.
    1. Routh A, Khansur T, Hickman BT, Bass D. Management of brain metastases: past, present, and future. South Med J. 1994;87:1218–26.
    1. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:1633–8.
    1. Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma: the second prospective randomized trial [Japanese] Nippon Igaku Hoshasen Gakkai Zasshi. 1994;54:1380–7.
    1. Gelber RD, Larson M, Borgelt BB, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981;48:1749–53.
    1. Nieder C, Nestle U, Niewald M, Schnabel K. Accelerated radiotherapy for brain metastases. Radiother Oncol. 1997;45:17–22.
    1. Portaluri M, Bambace S, Giuliano G, et al. Fractionations in radiotherapy of brain metastases. Tumori. 2004;90:80–5.
    1. Priestman TJ, Dunn J, Brada M, Rampling R, Baker PG. Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 1996;8:308–15.
    1. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:891–5.
    1. Bach F, Sorensen JB, Adrian L, et al. Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regiments of therapeutic brain irradiation. Lung Cancer. 1996;15:171–81.
    1. Johnson FE, Harrison BR, McKirgan LW, Raju PI, Roy TK, Virgo KS. A phase ii evaluation of pentoxifylline combined with radiation in the treatment of brain metastases. Int J Oncol. 1998;13:801–5.
    1. Kocher M, Eich HT, Semrau R, Güner SA, Müller RP. Phase i/ii trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol. 2005;181:20–5.
    1. Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E on behalf of the reach Study Group. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys. 2006;64:1023–30.
    1. Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy and temozolomide (tmz) is active and improves quality of life. BMC Cancer. 2007;7:18.
    1. Antonadou D, Coliarakis N, Paraskevaidis M, et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase iii study abstract. Int J Radiat Oncol Biol Phys. 2002;54:93–4.
    1. Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL. A randomised phase iii study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004;46:107–11.
    1. Hidalgo V, Dy C, Fernandez Hidalgo O, Calvo FA. Simultaneous radiotherapy and cis-platinum for the treatment of brain metastases. A pilot study. Am J Clin Oncol. 1987;10:205–9.
    1. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase ii randomized trial. Int J Radiat Oncol Biol Phys. 2005;61:185–91.
    1. Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery. 1991;28:201–5.
    1. Hazuka MB, Kinzie JJ. Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys. 1988;15:433–7.
    1. Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer. 1980;46:2587–9.
    1. Rosenman J, Choi NC. Improved quality of life of patients with small-cell carcinoma of the lung by elective irradiation of the brain. Int J Radiat Oncol Biol Phys. 1982;8:1041–3.
    1. Shehata WM, Hendrikson FR, Hindo WA. Radiofractionation technique and retreatment of cerebral metastases of irradiation. Cancer. 1974;34:257–61.
    1. Abdel–Wahab M, Wolfson A, Raub W, et al. The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol. 1997;20:158–60.
    1. Jawahar A, Ampil F, Wielbaecher C, Hartman GH, Zhang JH, Nanda A. Management strategies for patients with brain metastases: has radiosurgery made a difference? South Med J. 2004;97:254–8.
    1. Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol. 1998;16:3563–9.
    1. Kondziolka D, Niranjan A, Flickinger JC, et al. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients’ perspective regarding complications. Am J Clin Oncol. 2005;28:173–9.
    1. Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999;43:549–58.
    1. Scott C, Suh J, Stea B, Nabid A, Hackman J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol. 2007;30:580–7.
    1. Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002;38:487–96.
    1. Gerrard GE, Prestwich RJ, Edwards A, et al. Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 2003;15:422–8.
    1. Lock M, Chow E, Pond GR, et al. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? Clin Oncol (R Coll Radiol) 2004;16:332–8.
    1. Sehlen S, Lenk M, Hollenhorst H, et al. Quality of life (qol) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie. 2003;26:38–43.
    1. Yaneva MP, Semerdjieva MA. Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using eortc-qol-C30 questionnaire. Folia Medica. 2006;48:23–9.
    1. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007;25:1260–6.
    1. Regine WF, Schmitt FA, Scott CB, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys. 2004;58:1346–52.
    1. Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol. 1994;170:155–61.
    1. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (fact) scale. Development of a brain subscale and revalidation of the general version (fact-g) in patients with primary brain tumors. Cancer. 1995;75:1151–61.
    1. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5:139–50.
    1. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164–71.
    1. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J Chron Dis. 1981;34:585–97.
    1. Herman MA, Tremont–Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases. Am J Clin Oncol. 2003;26:273–9.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere